Log in
Many clinically-useful natural products fall into the class of polyketides. From 1993, research led by Professors Leadlay (Biochemistry) and Staunton (Chemistry) on polyketide biosynthesis pathways led to the foundation of the spin-out company Biotica Technology Ltd in 1996. Between 2008 and 2013 the company provided continuous employment for on average 15-20 highly-skilled scientists, and attracted additional investments of £4.43M. Its follow-on company Isomerase Therapeutics Ltd, founded by ex-Biotica researchers with Leadlay's support in 2013, has acquired compounds, strains and IP from Biotica. Using the methods developed in the University by Leadlay and Staunton, Biotica developed a HepC antiviral therapy, sold in 2013 to NeuroVive Pharmaceuticals AB and currently entering pre-clinical toxicology tests. Biotica have also licensed their technology to a number of companies globally, including GSK and Amyris.
Queen's University's Ionic Liquids Laboratory (QUILL) has developed an ionic liquid technology for removing mercury, a toxic, corrosive contaminant naturally present in hydrocarbon reserves, with the national oil and gas company Petroliam Nasional Berhad (PETRONAS).The technology has been successfully installed in 1-and 15-ton units in two PETRONAS gas processing plants in Malaysia. The process, marketed as HycaPure Hg™, captures all mercury species present in natural gas and has up to 3 times higher capacity than competing state-of-the-art commercial alternatives. This technology represents a significant improvement towards ensuring the health and safety of workers, process plant and the environment.
Techniques that can produce detailed chemical information rapidly and non-destructively for many forensic applications have been developed by Queen's University Belfast based on Raman analysis. The techniques have been adopted by the Forensic Science laboratory in Northern Ireland (FSNI) to trace the source of seized drugs, identify novel psychoactive substances ("legal highs") and study paint evidence. More than 2000 cases of supply/possession of ecstasy drugs, 947 paint casework samples and 100 'legal highs' have been analysed. Other law enforcement agencies are now adopting the methods developed at Queen's.
University of Huddersfield research in physical organic chemistry has delivered economic, industrial and societal benefits. It has led to process improvements in chemical manufacturing, most notably in the optimisation of the synthesis of antisense oligonucleotides and in the use of liquid ammonia as a solvent. It has also led to the development of new inhibitors of bacterial β-lactamases for use as antibacterials. The research team's expertise has been reflected in the success of IPOS (Innovative Physical Organic Solutions), a unit established in 2006 to carry out research in process and other areas of chemistry for the chemical industry. IPOS expanded significantly from 2009 to 2013 and has now collaborated with more than 150 companies, many of them based in Yorkshire/Humberside where regeneration is critically dependent on the success of new, non-traditional, high-technology firms and industries. Through these collaborative projects, IPOS has contributed to the growth and prosperity of both regional and national industry.
A portfolio of Oxford University research, relating to the chemistry of natural products extracted from plants, has formed the basis of a substantial and multifaceted programme of outreach activity targeted at schools and the general public from 2011-2013. Research students and staff have collaborated with the Oxford University Botanic Garden to deliver multiple events including a poster exhibition, an audio trail, interactive guided walks and a `solar fuels' stand at the prestigious 2013 Royal Society Summer Science Exhibition, with the emphasis on face-to-face in-depth interaction where possible and a strong link to Oxford Chemistry research. The events have educated thousands of people and helped to inform their views on, and enthusiasm for, plant-related chemistry. They have also engaged the interest and support of industry.
Cardiff University, through developing and patenting a commercially viable synthetic route to a catalyst, has enabled the application of a new process, the Alpha Process, for the production of methyl methacrylate (MMA), a key commodity precursor to Perspex. The Alpha Process has had economic and environmental impacts.
Lucite International, the world's leading MMA producer, has invested in major Alpha Process production facilities in Singapore and Saudi Arabia, benefitting from a production route which is more efficient, more reliable and cheaper than conventional routes.
The Alpha Process also brings environmental benefits, as it does not rely on the use of corrosive and toxic feedstocks, such as hydrogen cyanide, which are associated with conventional MMA processes.
The cost of goods is an especially important issue in developing commercially available agrochemicals, which must be manufactured on a large scale. Richard Compton's research at the University of Oxford has led to a step change in the understanding of heterogeneous reaction mechanisms for liquid — organic solid or liquid — inorganic solid processes involved in large-scale manufacturing processes. Compton's work has had particular impact on optimising the processes used by Syngenta AG in its manufacturing of agrochemicals. Since 2008 the insights gained on inorganic-base dissolution have been of great benefit to Syngenta in its development of scalable robust manufacturing processes, particularly in relation to production of its fungicide Amistar and insecticide Actara, which are two of the world's largest selling products of this type. In 2012 Syngenta achieved total sales of over $ 14 billion, $ 4.8 billion of this from fungicide and insecticide revenues.
The growth and performance of Biofocus Galapagos Argenta (BGA) and Pulmagen Therapeutics (PT) are underpinned by research from the Imperial-based TeknoMed project that started in 1997. BGA was formed in 2010 through the acquisition of Argenta Discovery (AD) by Biofocus Galapagos for €16.5 million and is one of the world's largest drug discovery service organisations with 390 plus employees and turnover of €135 million [section 5, A]. PT was formed as a separate company to own the complete AD drug pipeline. It develops new medicines to treat asthma, cystic fibrosis and allergic diseases. In 2011 BGA signed agreements with PT for an initial £6million fee and with Genentech for £21.5million.
University of Bath research has contributed to a lean, `build-to-order' (BTO) production strategy for the European automotive industry. The study of `intelligent logistics' and supply chain configurations led to recommendations for building new production systems that are helping to address significant industry problems: global overcapacity, rising stock levels and low profitability. The research findings have been widely shared with vehicle manufacturers, suppliers, industry trade associations and government bodies, original equipment manufacturers (OEMs) and suppliers. The Bath research has had an impact on: the reduction of waste that is integral to the former `build to stock' production model; the development of an environmentally friendly manufacturing approach; improved profitability through the reduction of `inventory' (new cars losing value in large distribution parks); and on future innovation and growth challenges for the automotive industry. The research has influenced manufacturers and suppliers seeking to implement a more flexible automotive component supply chain across Europe.
UCL research has been instrumental in creating critically needed new biocatalysts and bioprocess technologies for industrial biocatalytic process development. These have impact across the UK chemical and pharmaceutical sectors. BiCE enzyme technologies have been exploited through the formation of a spin-out company, Synthace, generating investment of £1.8m and creation of 7 new jobs. Commercial utilisation of BiCE enzymes by company partners has led to environmental benefits through sustainable syntheses and reduced waste generation. BiCE high-throughput bioprocess technologies have also been adopted to speed biocatalytic process development. UCL established a parallel miniature stirred bioreactor system as a new product line for HEL Ltd. [text removed for publication]. Related knowledge transfer activities have also benefited some 157 industrial employees from over 50 companies since 2008.